Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBIT Margin: 2017-2018

Historic EBIT Margin for Astria Therapeutics (ATXS) over the last 2 years, with Sep 2018 value amounting to 60,080.00%.

  • Astria Therapeutics' EBIT Margin rose 6286080.00% to 60,080.00% in Q3 2018 from the same period last year, while for Sep 2018 it was -17,186.67%, marking a year-over-year change of. This contributed to the annual value of 26,371.00% for FY2018, which is 3178980.00% up from last year.
  • According to the latest figures from Q3 2018, Astria Therapeutics' EBIT Margin is 60,080.00%, which was up 198.77% from 20,109.09% recorded in Q2 2018.
  • In the past 5 years, Astria Therapeutics' EBIT Margin ranged from a high of 60,080.00% in Q3 2018 and a low of -2,780.80% during Q3 2017.
  • In the last 2 years, Astria Therapeutics' EBIT Margin had a median value of 5,448.03% in 2017 and averaged 14,181.14%.
  • Data for Astria Therapeutics' EBIT Margin shows a peak YoY soared of 6,286,080bps (in 2018) over the last 5 years.
  • Over the past 2 years, Astria Therapeutics' EBIT Margin (Quarterly) stood at -2,198.80% in 2017, then skyrocketed by 6,286,080bps to 60,080.00% in 2018.
  • Its EBIT Margin was 60,080.00% in Q3 2018, compared to 20,109.09% in Q2 2018 and 13,401.75% in Q1 2018.